Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine for XMEN syndrome (single-arm, pediatric, Phase 4)
ChiCTR2600121130Phase 4Recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia (XMEN), sponsored by Children's Hospital of Fudan University. Primary endpoints: Cumulative incidence of Grade ≥3 myelosuppression, Change from baseline in NKG2D expression levels on peripheral blood lymphocytes and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
decitabine
03
Conditions
X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia (XMEN)
Beyond the preview
Go deeper on ChiCTR2600121130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121130.